BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 27531070)

  • 1. Feedback control of ErbB2 via ERK-mediated phosphorylation of a conserved threonine in the juxtamembrane domain.
    Kawasaki Y; Sakimura A; Park CM; Tomaru R; Tanaka T; Ozawa T; Zhou Y; Narita K; Kishi H; Muraguchi A; Sakurai H
    Sci Rep; 2016 Aug; 6():31502. PubMed ID: 27531070
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanisms for DNA-damaging agent-induced inactivation of ErbB2 and ErbB3 via the ERK and p38 signaling pathways.
    Park CM; Kawasaki Y; Refaat A; Sakurai H
    Oncol Lett; 2018 Feb; 15(2):1758-1762. PubMed ID: 29434871
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Flotillin depletion affects ErbB protein levels in different human breast cancer cells.
    Asp N; Pust S; Sandvig K
    Biochim Biophys Acta; 2014 Sep; 1843(9):1987-96. PubMed ID: 24747692
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation.
    Holbro T; Beerli RR; Maurer F; Koziczak M; Barbas CF; Hynes NE
    Proc Natl Acad Sci U S A; 2003 Jul; 100(15):8933-8. PubMed ID: 12853564
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Loss of Nrdp1 enhances ErbB2/ErbB3-dependent breast tumor cell growth.
    Yen L; Cao Z; Wu X; Ingalla ER; Baron C; Young LJ; Gregg JP; Cardiff RD; Borowsky AD; Sweeney C; Carraway KL
    Cancer Res; 2006 Dec; 66(23):11279-86. PubMed ID: 17145873
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heregulin-mediated ErbB2-ERK signaling activates hyaluronan synthases leading to CD44-dependent ovarian tumor cell growth and migration.
    Bourguignon LY; Gilad E; Peyrollier K
    J Biol Chem; 2007 Jul; 282(27):19426-41. PubMed ID: 17493932
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inverse correlation between Thr-669 and constitutive tyrosine phosphorylation in the asymmetric epidermal growth factor receptor dimer conformation.
    Sato K; Shin MS; Sakimura A; Zhou Y; Tanaka T; Kawanishi M; Kawasaki Y; Yokoyama S; Koizumi K; Saiki I; Sakurai H
    Cancer Sci; 2013 Oct; 104(10):1315-22. PubMed ID: 23822636
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuregulin-1 only induces trans-phosphorylation between ErbB receptor heterodimer partners.
    Li Z; Mei Y; Liu X; Zhou M
    Cell Signal; 2007 Mar; 19(3):466-71. PubMed ID: 16978839
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective hormone-dependent repression of estrogen receptor beta by a p38-activated ErbB2/ErbB3 pathway.
    St-Laurent V; Sanchez M; Charbonneau C; Tremblay A
    J Steroid Biochem Mol Biol; 2005 Feb; 94(1-3):23-37. PubMed ID: 15862947
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EGF receptor inhibitors increase ErbB3 mRNA and protein levels in breast cancer cells.
    Grøvdal LM; Kim J; Holst MR; Knudsen SL; Grandal MV; van Deurs B
    Cell Signal; 2012 Jan; 24(1):296-301. PubMed ID: 21951604
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dynamic analysis of the epidermal growth factor (EGF) receptor-ErbB2-ErbB3 protein network by luciferase fragment complementation imaging.
    Macdonald-Obermann JL; Adak S; Landgraf R; Piwnica-Worms D; Pike LJ
    J Biol Chem; 2013 Oct; 288(42):30773-30784. PubMed ID: 24014028
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypoxia/HIF1α induces lapatinib resistance in ERBB2-positive breast cancer cells via regulation of DUSP2.
    Karakashev SV; Reginato MJ
    Oncotarget; 2015 Feb; 6(4):1967-80. PubMed ID: 25596742
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased erbB3 promotes erbB2/neu-driven mammary tumor proliferation and co-targeting of erbB2/erbB3 receptors exhibits potent inhibitory effects on breast cancer cells.
    Lyu H; Huang J; Edgerton SM; Thor AD; He Z; Liu B
    Int J Clin Exp Pathol; 2015; 8(6):6143-56. PubMed ID: 26261492
    [TBL] [Abstract][Full Text] [Related]  

  • 14. c-Src modulates ErbB2 and ErbB3 heterocomplex formation and function.
    Ishizawar RC; Miyake T; Parsons SJ
    Oncogene; 2007 May; 26(24):3503-10. PubMed ID: 17173075
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estrogenic promotion of ErbB2 tyrosine kinase activity in mammary tumor cells requires activation of ErbB3 signaling.
    Liu B; Ordonez-Ercan D; Fan Z; Huang X; Edgerton SM; Yang X; Thor AD
    Mol Cancer Res; 2009 Nov; 7(11):1882-92. PubMed ID: 19861407
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functional cooperation of miR-125a, miR-125b, and miR-205 in entinostat-induced downregulation of erbB2/erbB3 and apoptosis in breast cancer cells.
    Wang S; Huang J; Lyu H; Lee CK; Tan J; Wang J; Liu B
    Cell Death Dis; 2013 Mar; 4(3):e556. PubMed ID: 23519125
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A feedback loop between androgen receptor and ERK signaling in estrogen receptor-negative breast cancer.
    Chia KM; Liu J; Francis GD; Naderi A
    Neoplasia; 2011 Feb; 13(2):154-66. PubMed ID: 21403841
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Negative feedback regulation of ErbB4 tyrosine kinase activity by ERK-mediated non-canonical phosphorylation.
    Haryuni RD; Watabe S; Yamaguchi A; Fukushi Y; Tanaka T; Kawasaki Y; Zhou Y; Yokoyama S; Sakurai H
    Biochem Biophys Res Commun; 2019 Jun; 514(2):456-461. PubMed ID: 31053301
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Downregulation of erbB3 abrogates erbB2-mediated tamoxifen resistance in breast cancer cells.
    Liu B; Ordonez-Ercan D; Fan Z; Edgerton SM; Yang X; Thor AD
    Int J Cancer; 2007 May; 120(9):1874-82. PubMed ID: 17266042
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Compensatory ErbB3/c-Src signaling enhances carcinoma cell survival to ionizing radiation.
    Contessa JN; Abell A; Mikkelsen RB; Valerie K; Schmidt-Ullrich RK
    Breast Cancer Res Treat; 2006 Jan; 95(1):17-27. PubMed ID: 16267617
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.